AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment

NACompletedINTERVENTIONAL

Enrollment

679

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

December 31, 2015

Study Completion Date

September 19, 2017

Conditions

Rheumatoid Arthritis

Interventions

DRUG

denosumab

denosumab administered subcutaneously

DRUG

placebo

placebo administered subcutaneously to match denosumab

Trial Locations (1)

Tokyo